Galectin Therapeutics (NASDAQ:GALT) Issues Earnings Results

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) released its earnings results on Monday. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01, FiscalAI reports.

Galectin Therapeutics Price Performance

NASDAQ GALT opened at $3.05 on Monday. The company has a 50-day simple moving average of $3.65 and a two-hundred day simple moving average of $3.22. Galectin Therapeutics has a 12-month low of $2.03 and a 12-month high of $7.13. The firm has a market cap of $200.87 million, a price-to-earnings ratio of -7.09 and a beta of 0.53.

Analyst Ratings Changes

GALT has been the topic of a number of recent research reports. Zacks Research raised Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Monday, September 14th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $11.00.

Read Our Latest Stock Analysis on Galectin Therapeutics

Galectin Therapeutics Company Profile

(Get Free Report)

Galectin Therapeutics is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company’s research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer. Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment.

Further Reading

Earnings History for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.